Herpes simplex virus infections

Lancet

Volumn 357, Issue 9267, 2001, Pages 1513-1518

  Whitley, Richard J ^a   Roizman, Bernard ^b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; FAMCICLOVIR; HERPES SIMPLEX VACCINE; PENCICLOVIR; VALACICLOVIR;

AGITATION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; DISORIENTATION; DRUG BIOAVAILABILITY; DRUG INDICATION; GENE THERAPY; HALLUCINATION; HERPES; HERPES SIMPLEX VIRUS; HUMAN; KIDNEY DISEASE; MOLECULAR BIOLOGY; MYOCLONUS; NEPHROTOXICITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TREMOR; VIRUS RESISTANCE;

EID: 0035849323     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)04638-9     Document Type: Review

References (35)

1. Roizman B. Herpesviridae. In: Howley RM, Knipe DM, eds. Fields' virology, 4th edn. New York: Lippincott Press (in press).
2. Roizman B, Knipe DM. The replication of herpes simplex virus. In: Howley RM, Knipe DM, eds. Fields' virology, 4th edn. New York: Lippincott Press (in press).
3. Ward PL, Roizman B. Herpes simplex genes: the blueprint of a successful human pathogen. Trends Genet 1994; 10: 267-74.
4. Forrester A, Farrell H, Wilkinson G, Kaye J, Davis-Poynter N, Minson T. Construction and properties of a mutant herpes simplex virus type 1 with glycoprotein gH coding sequences deleted. J Virol 1992; 66: 341-48.
5. Flicker J. Herpes vaccines: spinning a new DISC. Lancet 1996; 348: 1576.
6. Chou J, Kern ER, Whitley RJ, Roizman B. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth inculture. Science 1990; 250: 1262-66.
7. Stevens JG, Cook ML. Latent herpes simplex virus in spinal ganglia. Science 1971; 173: 843-45.
8. Whitley RJ. Herpes simplex virus. In: Howley RM, Knipe DM, eds. Fields' virology, 4th edn. New York: Lippincott Press (in press).
9. Nahmias AJ, Lee FK, Bechman-Nahmias S. Sero-epidemiological and sociological patterns of herpes simplex virus infection in the world. Scand J Infect Dis 1990; 69: 19-36.
10. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976to 1994. N Engl J Med 1997; 337: 1105-11.
11. Wald A, Corey L, Cone R, Hobson A, Davis G, Zeh J. Frequent genital herpes simplex virus 2 shedding in immunocompetent women: effect of aciclovir treatment. J Clin Investig 1997; 99: 1092-97.
12. Lakeman FD, Whitley RJ, the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Diagnosis of herpes simplex encephalitis: application of polymerase chain reaction to cerebrospinal fluid from brain biopsied patients and correlation with disease. J Infect Dis 1995; 172: 857-63.
13. Spruance SL, Overall JC Jr, Kern ER, Krueger GG, Pliam V, Miller W. The natural history of recurrent herpes simplex labialis-implications for antiviral therapy. N Engl J Med 1977; 297: 69-75.
14. Corey L, Adams H, Brown ZA, Holmes K. Genital herpes simplex virus infections: clinical manifestations, course and complications. Ann Intern Med 1983; 98: 958-72.
15. Corey L. The diagnosis and treatment of genital herpes. JAMA 1982; 248: 1041-49.
16. Mertz GJ, Benedett J, Ashley R, Selke S, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992; 16: 197-202.
17. Wald A, Zeh J, Selke S, Ashley RL, Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 1995; 333: 770-75.
18. Brown ZA, Benedetti JK, Watts DH, et al. A comparison between detailed and simple histories in the diagnosis of genital herpes complicating pregnancy. Am J Obstet Gynecol 1995; 172: 1299-303.
19. Whitley RJ, Gnann JW. The epidemiology and clinical manifestations of herpes simplex virus infections. In: Roizman B, Whitley RJ, Lopez C, eds. The human herpes viruses. New York: Raven Press, 1993: 69-105.
20. Balfour HH Jr. Antiviral drugs. N Engl J Med 1999; 340: 1255-68.
21. Reichman RC, Badger GJ, Mertz GJ, Corey L. Treatment of recurrent genital herpes simplex infection with oral aciclovir: controlled trial. JAMA 1984; 251: 2103-07.
22. Diaz-Mitoma F, Sibbald RG, Shafran SD, Boon R, Saltzman RL. Oral famciclovir for the suppression of recurrent genital herpes - a randomized controlled trial: Collaborative Famciclovir Genital Herpes Research Group. JAMA 1998; 280: 928-29.
23. Patel R, Bodsworth NJ, Woolley P, et al. Valaciclovir for the suppression of recurrent genital HSV infection - a placebo controlled study of once daily therapy: International Valaciclovir HSV Study Group. Genitourin Med 1997; 73: 105-09.
24. Straus SE, Takiff HE, Seidlin M, et al. Suppression of frequently recurring genital herpes: placebo-contre lied double-blind trial of oral aciclovir. N Engl J Med 1984; 310: 1545-50.
25. Douglas JM, Critchlow C, Benedetti J, et al. A double-blind study of oral aciclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med 1984; 310: 1551-56.
26. Saral R, Burns WH, Laskin OL, Santos GW, Leitman PS. Aciclovir prophylaxis of herpes simplex virus infections: a randomized, double-blind, controlled trial in bone-marrow-transplant recipients. N Engl J Med 1981; 305: 63-67.
27. Whitley RJ, Alford CA, Hirsch MS, et al. Vidarabine versus aciclovir therapy in herpes simplex encephalitis. N Engl J Med 1986; 314: 144-49.
28. Whitley R, Arvin A, Prober C, et al. Predictors of morbidity and mortality in neonates with herpes simplex virus infections. N Engl J Med 1991; 324: 450-54.
29. Kimberlin DW, Lakeman FD, Arvin AM, et al. Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. J Infect Dis 1996; 174: 1162-67.
30. Erlich KS, Mills J, Chatis P, et al. Aciclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med 1989; 320: 293-96.
31. Burke RL. Current status of HSV vaccine development. In: Roizman B, Whitley RJ, Lopez C, eds. The human herpes viruses. New York: Raven Press, 1993: 367-79.
32. Corey L, Langenberg AG, Ashley R, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection-two randomized controlled trials: Chiron HSV Vaccine Study Group. JAMA 1999; 28: 379-80.
33. Spruance SL, SmithKline Beecham (SB) Herpes Vaccine Efficacy Study Group. In: Gender specific efficacy of a prophylatic SBAS4-adjuvanted γD2 subunit vaccine against genital herpes disease (GHD): Results of two clinical efficacy trials. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sept 17-20; Toronto, Canada.
34. Marken JM, Gillespie YG, Weichselbaum RR, Roizman B, Whitley RJ. Genetically engineered HSV in the treatment of glioma: a review. Rev Med Virol 2000; 10: 17-30.
35. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000; 7: 867-74.d